H. Lundbeck A/S (HLUBF)
H. Lundbeck A/S operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Valby, CR, DK. The stock last traded at $5.43, up 0.00% on the session, giving a market capitalisation of $5.76B. On trailing twelve-month figures it carries a trailing P/E of 11.20, a net margin of 14.7%. Its beta of 0.26 implies it has historically moved less than the broad market.
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. It operates through the following geographical segments: Europe, United States, and International Operations. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.
H. Lundbeck A/S is most often compared with the following Healthcare names: